INR ONLINE - Media Releases & Awards

By: Inr Online  05-Apr-2012
Keywords: Pilot, Pharmacists, Community Pharmacy

All is ready for the launch of the Pharmaceutical Society's community pharmacy Anti-coagulation Management Service pilot in November.

Thirty pharmacists from 15 pilot pharmacies across the country are scheduled to attend a training day on 5 November.

Successful training and subsequent accreditation is the prerequisite for all pharmacists who will be involved in providing the service through the pilot sites. The AMS pilot is currently awaiting ethics committee approval.

Health Workforce NZ approved funding earlier this year. It will involve enrolment of 50 atrial fibrillation patients at each site. These patients will be offered anticoagulation point of care testing using Roche Diagnostics' CoaguChek

meters and INR Online.

The pilot is aligned with the Midland Clinical Network's EoI business case under health minister Tony Ryall’s “Better, Sooner, More Convenient care”. The minister is reportedly keeping a close eye on the project due to its significance in integrating pharmacist services with wider primary healthcare.

Pharmaceutical Society president Elizabeth Plant says patient enrolment is expected to commence within two weeks of the pharmacists completing their training and accreditation.

The training day on 5 November, she says, will include a combination of theory and practice components to provide a focussed update on anticoagulation (specifically on warfarin management); standing orders under which pharmacists will operate and the communication policy around that and the use of CoaguCheck and INR Online.

Pharmacists will need to demonstrate competence through assessments that will be carried out throughout the day on various components of the training programme.

Mrs Plant says this programme could be used as an accredited training programme when AMS is widely rolled out in community pharmacy.

The 15 pilot sites are in Mount Maunganui (Tauranga), New Plymouth, Elmwood (Christchurch), Putararu, Kawerau, Manurewa, Glen Eden, Manukau (Auckland), Miramar (Wellington), Greymouth, NaeNae (Lower Hutt), Greenmeadows (Napier), Rotorua, Tokoroa and Huntly West.

Julie Kilkelly, owner of one of the pilot sites (Unichem Olsen’s Pharmacy, Greymouth), says she is excited about being a part of a professional service that will make a huge difference to her community.

“It is very difficult to get a doctor’s appointment in this area and even practice nurses are under immense pressure. But pharmacy can manage [anticoagulation] quite well, resulting in better, sooner, more convenient service to the patients,” Ms Kilkelly enthuses, adding that enrolling the requisite 50 patients will not be a problem.

The pharmacy has recently moved to new purpose-built premises with three consulting rooms.

The AMS project is led by a steering group including Mrs Plant, pharmacists Ian McMichael and Alice Wood (from Hamilton’s Pharmacy 547), Ann Privett, Dale Griffiths, the society chief executive Richard Townley, Otago University Christchurch professor of general practice, Les Toop, Auckland pharmacy school dean John Shaw, consultant haematologist Paul Harper, Midland Clinical Network's Amanda Kiss and Bronwyn Sheppard and Keryn Smith from Roche Diagnostics.

The AMS project is being seen as an excellent demonstration of the comprehensive medicines management service as envisaged under the National Pharmacist Services Framework.

The international normalised ratio (INR) is used to monitor patients receiving warfarin for treatment or prevention of thrombosis and embolism. The therapeutic range of warfarin is narrow, so monitoring of INR is performed to avoid complications from both over-dosage (which increases the risk of haemorrhagic events) and under-dosage (which may result in thromboembolic events).
In New Zealand, most patients prescribed warfarin have their INR levels measured in a laboratory and receive advice from general practice on their next dose and testing frequency. Some general practices have moved away from laboratory based INR testing and have adopted surgery based INR point-of-care testing (POCT) using portable coagulometers.
In 2009 a pilot was undertaken for INR testing and warfarin management using POCT in a community pharmacy setting. It is now being followed by a larger pilot study. The future of INR monitoring could be changing with testing and management increasingly coming into the care of community pharmacies.
It is likely that there will be a mixed response to community pharmacists adopting the role of INR testing. Some GPs and practice nurses may not be overly concerned and may even be pleased by the prospect of having one less task to worry about in their already-stretched workload. Others may feel that if the task of INR monitoring is mismanaged there could be serious consequences and so may be concerned to see it delegated outside of general practice.

Community pharmacy based INR point-of-care testing pilot

New Zealand’s first trial in community pharmacy-based POCT of INR took place in 2009. An anticoagulation clinic was set up at one community pharmacy using a portable coagulometer and a web-based management support tool, which allowed a revised warfarin dose to be calculated from the INR result. Patients were shown a pictorial representation of their warfarin dose and informed when their next test was required. The process took on average less than ten minutes to complete and also provided a chance to counsel patients about their warfarin management at each appointment.
The pilot study ran from July to November 2009, and involved 40 patients with prior consent from their GP. Results have not yet been published.

INR point-of-care-testing is quick and simple to perform

POCT of INR is performed by obtaining a drop of capillary blood from a patient via fingerprick which is then processed in a portable coagulometer. An INR result is usually obtained within three minutes.
Advantages of POCT of INR include:

  • INR results are obtained sooner allowing discussion of the result and any change in management at the same visit as the INR testing
  • It is a more acceptable method for people who have fears of venepuncture
  • It is more convenient for patients especially if they live some distance from phlebotomy services
  • Possibly improved compliance with warfarin as a result of having face-to-face guidance given rather than over-the-phone

The risks of POCT are those associated with obtaining the capillary sample including: localised bleeding, bruising and vasovagal episodes. There is also a risk of needle-stick injury when obtaining the sample but this is unlikely to pose any additional risk to that associated with venepuncture for laboratory-based INR testing.

Larger pilot trial currently planned

After observing the original pilot study, the Pharmaceutical Society of New Zealand supported the extension of the programme nationally and has planned a community pharmacy Anticoagulation Management Service pilot. This pilot will involve 15 pharmacies, each of which will enrol 50 patients with atrial fibrillation using warfarin. The pilot will run for one year, with an evaluation planned before the end of 2011.1
As with the original pilot study, the accredited pharmacists during this POCT of INR trial will:

  • Check the patient’s INR levels
  • Input the result into a computer programme for dose recommendation
  • Advise the patient of their next appropriate warfarin dose
  • Notify the GP of the blood result, dose and date of next test for the patient

The pharmacists will perform these tasks under standing orders from the patient’s GP, with communication protocols in place to ensure the GP remains fully informed and in charge of their patient’s care. The aim is to maintain INR levels within safe parameters. Appropriate protocols will be put in place for referral back to the patient’s GP, if required.1

Reaction to the proposed pilot study

The pilot POCT study is an opportunity for a partnership between pharmacy and general practice and for maximisation of pharmacists’ skills. However, it has been suggested that trialling of POCT for INR should also be carried out in a general practice setting for a true comparison of services.
There is concern that patients undergoing anticoagulation management, who are not regularly seen in general practice, will have compromised care. Anticoagulation management is multifactorial and complex, and patients have multiple needs in addition to a check of their INR level.
On the other hand, the number of people receiving oral anticoagulation therapy, most commonly for stroke prevention in non-valvular atrial fibrillation, is growing each year, with the increasingly ageing population. Increasing demand for monitoring could stretch the resources of general practice, if it is continued to be managed there alone.2
The question of cost has not been fully addressed. It is unclear whether individual pharmacies will purchase the necessary equipment for POCT and in turn, what cost will be passed on to the patient, bearing in mind that current laboratory testing of INR is fully funded.
It is likely that the results of the Anticoagulation Management Service pilot will answer some of these questions and help to determine whether INR testing fits into the community pharmacy setting, both in terms of patient and clinician satisfaction and improved patient safety.

The benefits of point-of-care testing of INR

An essential aspect of improving health services in New Zealand is to encourage the provision of better and convenient access to healthcare for all patients, particularly those with chronic illnesses and those who encounter barriers to accessing services. POCT represents a way to provide a convenient service, faster results and to facilitate quicker clinical decisions.
General Practices, with a desire to provide this service and the necessary resources and capacity, are an ideal setting for POCT of INR. It is also increasingly recognised that pharmacists are well-placed to provide patient-centred services such as POCT. Similar developments involving community pharmacists are taking place in the UK, Canada and South Africa.2 Community delivery of POCT for INR could also take place in residential aged-care facilities, led by pharmacists or general practice staff.
POCT of INR does not appear to be better than laboratory testing of INR, but it is at least as accurate and at least as effective in maintaining INR in the target range. It is also likely to be more convenient for many patients.

Is POCT of INR accepted by patients?

One study of POCT of INR by nurses in a general practice setting, found that significantly more patients preferred POCT of INR compared to usual care i.e. laboratory testing. This was due to factors such as improved capacity to make appointments, less time spent at appointments, less pain associated with the test and improved communication about medicine dose.3
Research in the UK, as part of a project on monitoring of diabetes and chronic heart disease using POCT, indicated that 34% of patients chose their pharmacy to monitor their condition instead of their GP. Of this 34%, almost all (97%) rated the pharmacy service better or equal to their GP. Convenience, both in terms of location and opening hours, is a key advantage of pharmacy based POCT.2

Is POCT of INR as accurate as laboratory testing?

In a general practice based study, calibrations of POCT and laboratory testing showed dependable INR levels from both systems.4
Community pharmacy-based POCT of INR has also been shown to be as accurate as laboratory INR monitoring. A study involving POCT at 16 rural pharmacies in Australia found the same results when 120 INR tests performed in the pharmacy setting were compared with laboratory tests taken within four hours.5

Are target INR levels achieved with POCT?

There is mixed evidence of the benefit of POCT compared to laboratory testing in maintaining INR within the target range, however POCT appears to be at least as effective.
A US-based observational study in a primary care clinic found a significant improvement in the percentage of visits in which a patient’s INR result was in the target range after POCT was implemented (from 34% to 67% over one year).6 In a more recent randomised controlled trial of POCT in general practice in Australia, there was no significant difference between the POCT and control groups (who received the usual laboratory based testing) in terms of the number of patients with results in the target range for INR (57% POCT vs 61.5% control, p=0.24).7 Another randomised controlled trial also found that there was no significant improvement in the time spent in the INR target range, between those who received POCT in a community clinic and those who received laboratory testing.4
One pharmacy-based study found that more than 80% of patients receiving POCT of INR had values within their targeted range 60% or more of the time, which is comparable with values reported for anticoagulation clinics.8

Is POCT of INR cost-effective?

There is currently no strong evidence of the cost–effectiveness of POCT of INR in either the general practice or community pharmacy setting. New Zealand specific data is required in order to accurately estimate the cost of POCT in this country.
A large trial in a general practice setting in Australia found there was no significant difference in overall costs between POCT and laboratory testing. There was a non-significant decrease in hospital admissions for patients using POCT of INR. POCT of INR increased the number of tests that people were receiving compared to those receiving laboratory tests. Overall, it was concluded that POCT of INR was not cost-effective in the general practice setting compared to usual care.9
Several other studies have concluded that POCT in a general practice setting is more expensive than laboratory testing.7,10 However, other studies have found that POCT provided an overall saving for health care providers or from a patient perspective, through a reduction in patient visits to the GP.6,11–13

Warfarin is underused in areas with limited access to pathology services

Research shows that warfarin may often be underused in areas in which access to pathology services for INR monitoring is limited. Patients in these areas who do use warfarin are also potentially at increased risk of under- or over-dosing events.15 The availability of portable INR monitors in such settings would be likely to increase the level and safety of warfarin use.
A Canadian study found that both physician and pharmacist-managed anticoagulation services were associated with improved INR control, but pharmacist-managed services may be more expensive in the long-term.14
It is difficult to calculate cost in terms of just economic value. Costs may be offset by prolonged life or reduced hospital stays.9

  1. Pharmacy Today. Pharmacy steps up to challenge. 2010; Sept. Available from: (Accessed September, 2010).
  2.  St John A. The evidence to support point-of-care testing. Clin Biochem. Rev 2010 August;31(3):111-9.
  3. Chaudhry R, Scheitel S, Stroebel R, et al. Patient satisfaction with point-of-care international normalised ratio testing and counselling in a community internal medicine practice. Manag Care Interface 2004;17:44-6.
  4.  Shiach C, Campbell B, Poller L, et al. Reliability of point-of-care prothrombin time testing in a community clinic: a randomised crossover comparison with hospital laboratory testing. Br J Haematol 2004;127:373-8.
  5. Jackson S, Peterson G, Bereznicki L, et al. Improving the outcomes of anticoagulation in rural Australia: an evaluation of pharmacist-assisted monitoring of warfarin therapy. J Clin Pharm Ther 2005;30(4):345-53.
  6. Wurster M, Doran T. Anticoagulation management: a new approach. Dis Manag 2006;9:201–9.
  7. Bubner TK, Laurence CO, Gialamas A, et al. Effectiveness of point-of-care testing for therapeutic control of chronic conditions: results from the PoCT in General Practice Trial. Med J Aust 2009;190:624–6.
  8. Knowlton C, Thomas O, Williamson A, et al. Establishing community pharmacy-based anticoagulation education and monitoring programs. J Am Pharm Assoc 1999;39(3):368-74.
  9. Laurence C, Moss J, Briggs N, et al. The cost-effectiveness of point of care testing in a general practice setting: results from a randomised controlled trial. BMC Health Services Research 2010;10:165.
  10. Parry D, Fitzmaurice D, Raftery J. Anticoagulation management in primary care: a trial-based economic evaluation. Br J Haematol 2000;111:530-3.
  11. Claes N, Buntinx F, Vijgen J, et al. The Belgian improvement study on oral anticoagulation therapy: a randomised clinical trial. Eur Heart J 2005;26:2159-65.
  12. Parry D, Bryan S, Gee K, et al. Patient costs in anticoagulation management: a comparison of primary and secondary care. Br J Gen Pract 2001;51:972-6.
  13. 13. Fitzmaurice D, Hobbs F, Murray E. Primary care anticoagulant clinic management using computerised decision support and near patient international normalised ration (INR) testing: routine data from a practice nurse-led clinic. Fam Pract 1998;15:144-6.
  14. Lalonde L, Martineau J, Blais N, et al. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomised controlled trial. Am Heart J 2008;156(1):148-54.
  15. Jackson S, Peterson G. Point-of-care monitoring of anticoagulant therapy by rural community pharmacists: Description of successful outcomes. Aust J Rural Health 2004;12(5): 197-200.

The Pharmacy Guild of New Zealand (the Guild) is welcoming Health Workforce New Zealand’s decision to fund up to 15 community pharmacy pilot sites to provide anticoagulation therapy to patients.
This anticoagulation management services project will allow community pharmacists to play a greater role in managing patients on long term warfarin therapy. They will have the authority to modify warfarin prescriptions for stable patients in collaboration with general practice.
“This project recognises the crucial role that community pharmacists play as members of the primary health care team,” says Ian Johnson, Guild President and pharmacy owner. “The pilot will provide a significant improvement in health outcomes for patients. It will help patients better manage their condition and it also means they only need to go to one place to receive the care they need from the medicines experts.”
Pilot sites will be established from October and pharmacies that wish to be considered will need to meet certain prerequisites. Selected pharmacists will undergo specific training and assessment. ENDS

Software that helps patients taking warfarin to check their blood clotting factor at home is attracting national attention and on the way to exploring an international market.
The INRonline management system, designed by MidCentral Health consultant haematologist Paul Harper and his son, software developer Joe Harper, is one of 10 finalists in the New Zealand Focus on Health Challenge, run by New Zealand Trade and Enterprise.
Last year it won a MidCentral District Health Award for innovation, and it's already a winner with one of its first users, Palmerston North heart patient Howard Ball.
He's been on the blood-thinning drug to protect against the clots that are a risk with his irregular heart beat – the most common reason for being prescribed the drug long term – for about six years.
He found the previous methods for monitoring his condition "a bloody nuisance".
Before the INRonline system, he had to go to the laboratory every month to have a blood sample taken. The results went to his doctor, and if they weren't in the desired range, they'd have to make contact and arrange a dose change.
When he was travelling away from home, getting to a laboratory was even more of a hassle.
Dr Harper said under that system, the 40,000-plus New Zealanders taking the drug weren't getting ideal results about 58 per cent of the time. The danger was that if they took too much, they could bleed too easily, and if they didn't get enough, dangerous clots could form. In the Palmerston North trial, patients achieved a good level of management 80 per cent of the time.
The test kits are rather like a diabetic's, with sharps to draw a bead of blood from the finger, a test strip to collect the blood, and an electronic reading device.
Mr Ball knew they were available years ago, but couldn't afford one. And Dr Harper said the next step was missing – knowing what to do with the result. INRonline allows users to get online advice if a change in dose is needed.
"There are trials using internet contact between patient and doctor, but nor this sort of software that interprets the results, provides feedback to the patient, and flags irregular results to the doctor."
That allows for close medical supervision without the patient having to leave home, or alternatively, lets patients travel abroad and still have monitoring and advice on hand.
Mr Ball can carry out the test in a few minutes from home whenever it suits him, and gets an email reminder.
He runs the test, logs on, and answers a few questions about whether he's missed his pills, started taking any other medication, or has had any recent bleeding or bruising.
On the day he demonstrated, his INR (International Normalised Ratio) was 2.7 – safely within his ideal range.
The computer software responded telling him how much warfarin he should be taking – the dose was unchanged – and even produced a printable calendar showing him how many of which dose tablets he should be taking on each day.
"The convenience is absolutely superb," Mr Ball said, even at dial-up speed.
Since the system was trialled in Palmerston North about 60 patients have bought the $1000 test kit, and some can get subsidies for the test strips.
Another 70 people are on a nurse-led trial around East Cape, and a few pharmacies are offering an in-store test that links into the online programme, bringing the total number of users to around 500.
Dr Harper said gaining recognition in the health challenge awards gave him access to expert advice on business development, legal and marketing advice. And the potential market was global.
The winner of the awards will be announced next year.

The warfarin self-testing project using INR online and the CoaguChek won the Innovation category at the Midcentral Health Awards. The project was up against 10 other entries in the innovation category.
The judges comments: "The winner combined a complex medical field with the ingenuity of a passionate software designer to radically change the management of the drug warfarin"
WINNER - Best presentation at Health Informatics New Zealand Conference 2005
This presentation outlines how an internet based computer system could improve anticoagulant management.

The information in this article was current at 27 Mar 2012

Keywords: Anticoagulation, Community Pharmacy, Pharmacists, Pilot